Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population

BMC Medical Genetics

Volumn 10, Issue , 2009, Pages

  Kudzi, William ^a,b   Dodoo, Alexander N O ^b   Mills, Jeremy J ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b UNIVERSITY OF GHANA   (Ghana)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYP2C19 PROTEIN, HUMAN; CYP2C8 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; ASIAN; CAUCASIAN; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GHANA; HUMAN; HUMAN EXPERIMENT; INDIGENOUS PEOPLE; MALE; NEGRO; NORMAL HUMAN; POPULATION RESEARCH; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; GENE LINKAGE DISEQUILIBRIUM; GENETICS;

TETRA;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENE FREQUENCY; GENOTYPE; GHANA; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 73149102765     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-10-124     Document Type: Article

References (43)

1. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002, 12(2):121-132. 10.1097/00008571-200203000-00006, 11875366.
2. Garcia-Martin E, Martinez C, Ladero JM, Agundez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006, 10(1):29-40.
3. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001, 52(4):349-355. 10.1046/j.0306-5251.2001.01499.x, 2014584, 11678778.
4. Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003, 192(1):23-32. 10.1016/S0300-483X(03)00247-6, 14511900.
5. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrere N, Maurel P. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 2001, 29(3):242-251.
6. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001, 11(7):597-607. 10.1097/00008571-200110000-00006, 11668219.
7. Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, De Faire U, Rane A. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 2003, 13(12):715-720. 10.1097/00008571-200312000-00002, 14646690.
8. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998, 45(6):525-538. 10.1046/j.1365-2125.1998.00721.x, 1873650, 9663807.
9. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002, 54(10):1257-1270. 10.1016/S0169-409X(02)00076-5, 12406644.
10. Martinez C, Blanco G, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, Diaz-Rubio M, Agundez JA. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol 2004, 141(2):205-208. 10.1038/sj.bjp.0705623, 1574205, 14707031.
11. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005, 7(2):97-104. 10.1002/ajmg.a.30391, 15714076.
12. Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001, 11(4):287-291. 10.1097/00008571-200106000-00002, 11434505.
13. Whatman FTA Protocol. , http://www.kirkhousetrust.org/Docs/FTAProtocolBD08.pdf
14. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002, 64(11):1579-1589. 10.1016/S0006-2952(02)01354-0, 12429347.
15. Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 2003, 56(6):653-657. 10.1046/j.1365-2125.2003.01937.x, 1884305, 14616425.
16. Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E. Two single-tube tetra-primer assays to detect the CYP2C19*2 and *3 alleles of S-mephenytoin hydroxylase. Clin Chem 2001, 47(4):772-774.
17. Rower SBU, Weise A, Lambertz U, Frost T, Otchwemah RN, Pfutzner A, Mockkenhaupt F. High prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Tropical Medicine and International Health 2005, 10(12):1271-1273.
18. Dreisbach AW, Japa S, Sigel A, Parenti MB, Hess AE, Srinouanprachanh SL, Rettie AE, Kim H, Farin FM, Hamm LL. The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens 2005, 18(10):1276-1281. 10.1016/j.amjhyper.2005.04.019, 16202848.
19. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 2007, 82(2):197-203. 10.1038/sj.clpt.6100122, 17361129.
20. Cavaco I, Stromberg-Norklit J, Kaneko A, Msellem MI, Dahoma M, Ribeiro VL, Bjorkman A, Gil JP. CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol 2005, 61(1):15-18. 10.1007/s00228-004-0871-8, 15785959.
21. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, Rane A. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 2002, 299(1):25-28. 10.1016/S0006-291X(02)02592-5, 12435384.
22. Weise A, Grundler S, Zaumsegel D, Klotzek M, Grondahl B, Forst T, Pfutzner A. Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. Clin Lab 2004, 50(3-4):141-148.
23. Rower S, Bienzle U, Weise A, Lambertz U, Forst T, Otchwemah RN, Pfutzner A, Mockenhaupt FP. Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop Med Int Health 2005, 10(12):1271-1273.
24. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001, 52(4):447-450. 10.1046/j.0306-5251.2001.01460.x, 2014581, 11678789.
25. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 1997, 7(3):203-210. 10.1097/00008571-199706000-00005, 9241660.
26. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000, 10(2):95-104. 10.1097/00008571-200003000-00001, 10761997.
27. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 2003, 33(Suppl 2):23-30. 10.1046/j.1365-2362.33.s2.6.x, 14641553.
28. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002, 12(3):251-263. 10.1097/00008571-200204000-00010, 11927841.
29. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996, 44(7):751-755.
30. White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999, 107(5):414-424. 10.1016/S0002-9343(99)00267-3, 10569295.
31. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994, 46(4):594-598.
32. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994, 269(22):15419-15422.
33. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997, 7(1):59-64. 10.1097/00008571-199702000-00008, 9110363.
34. Dandara C, Masimirembwa CM, Magimba A, Sayi J, Kaaya S, Sommers DK, Snyman JR, Hasler JA. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol 2001, 57(1):11-17. 10.1007/s002280100282, 11372584.
35. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frotschl R, Kopke K, Gerloff T, Chernov JN, Roots I. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003, 59(4):303-312. 10.1007/s00228-003-0606-2, 12879168.
36. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994, 4(6):285-299. 10.1097/00008571-199412000-00001, 7704034.
37. Fukushima-Uesaka H, Saito Y, Maekawa K, Ozawa S, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N. Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab Pharmacokinet 2005, 20(4):300-307. 10.2133/dmpk.20.300, 16141610.
38. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003, 13(2):89-95. 10.1097/00008571-200302000-00005, 12563178.
39. Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C, Freymann N, Zobel A, Maier W, Rao ML. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004, 60(5):329-336. 10.1007/s00228-004-0766-8, 15168101.
40. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993, 27(7-8):832-840.
41. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama 1998, 279(15):1200-1205. 10.1001/jama.279.15.1200, 9555760.
42. Bosch TM, Doodeman VD, Smits PH, Meijerman I, Schellens JH, Beijnen JH. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Mol Diagn Ther 2006, 10(3):175-185.
43. Adithan C, Gerard N, Vasu S, Rosemary J, Shashindran CH, Krishnamoorthy R. Allele and genotype frequency of CYP2C19 in a Tamilian population. Br J Clin Pharmacol 2003, 56(3):331-333. 10.1046/j.1365-2125.2003.01883.x, 1884356, 12919183.